• 1
    Gontero P, Banisadr S, Frea B, Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol. 2004; 46: 296-311.
  • 2
    Becker M, Tilki D, Szarvas T, Rubben H, Ergun S. Urine-based markers of angiogenesis in bladder cancer. Urologe A. 2009; 48: 609-614.
  • 3
    Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997; 78: 285-296.
  • 4
    Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 1999; 71: 130-135.
  • 5
    Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol. 1995; 8: 291-312.
  • 6
    Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004; 91: 450-456.
  • 7
    Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002; 26: 767-771.
  • 8
    Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer. 1997; 71: 116-122.
  • 9
    Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998; 4: 923-928.
  • 10
    Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 B breast cancer cells. J Biol Chem. 2002; 277: 40950-40957.
  • 11
    Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer. 2000; 82: 1702-1708.
  • 12
    Lademann UA, Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost. 2008; 100: 1041-1046.
  • 13
    Span PN, Witjes JA, Grebenchtchikov N, et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int. 2008; 102: 177-182.
  • 14
    Droller MJ. Markers in bladder cancer. Issues to consider. J Urol. 1998; 160: 2009-2010.
  • 15
    Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000; 163: 60-61.
  • 16
    Eble JN, Epstein JI, Sesterhenn I. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 89-158.
  • 17
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC[T]) methods. Methods. 2001; 25: 402-408.
  • 18
    Ergun S, Kilik N, Ziegeler G, et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor. Mol Cell. 2000; 5: 311-320.
  • 19
    Bashar H, Urano T, Fukuta K, et al. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int. 1994; 52: 4-8.
  • 20
    Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001; 12: 51-58.
  • 21
    Palmirotta R, Ferroni P, Savonarola A, et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res. 2009; 124: 403-408.
  • 22
    Torii K, Kimura H, Li X, et al. Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples. Rinsho Byori. 2004; 52: 506-512.
  • 23
    McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2007; 36: 184-194.
  • 24
    Sternlicht MD, Dunning AM, Moore DH, et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2107-2114.
  • 25
    Kuhn W, Schmalfeldt B, Reuning U, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIC. Br J Cancer. 1999; 79: 1746-1751.
  • 26
    Chen SC, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol. 2009; 181: 336-342.
  • 27
    Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 1996; 77: 1079-1088.
  • 28
    Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 6: 8319-8326.
  • 29
    Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004; 23: 6986-6990.
  • 30
    Devy L, Blacher S, Grignet-Debrus C, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 2002; 16: 147-154.
  • 31
    Frandsen TL, Holst-Hansen C, Nielsen BS, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res. 2001; 61: 532-537.